Synapse - Works

Results (5608)

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Tannir, N. M.; Frontera, O. A.; Hammers, H. J.; Carducci, M. A.; McDermott, D. F.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; Porta, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N + I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthelemy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Kollmannsberger, C. K.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD

Meeting Abstract

Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P.; Yu, E. Y.; George, D. J.; Chi, K. N.; Summa, J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends

Meeting Abstract

Rosenthal, K.; Galsky, M. D.; Milowsky, M. I.; Petrylak, D. P.; Rosenberg, J. E.; Obholz, K.; Plimack, E. R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer

Meeting Abstract

Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Hullings, M.; Carbone, E.; Barnett, E.; Sutton, R.; Jendrisak, A.; Landers, M. A.; Wang, Y.; Dittamore, R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Meeting Abstract

Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC)

Meeting Abstract

Petrylak, D. P.; Rosenberg, J. E.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E. M.; Melhem-Bertrandt, A.; Powles, T.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Rini, B. I.; Escudier, B.; Murphy, D.; Wang, P.; Tarazi, J. C.; Motzer, R. J.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Time to PSA nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy

Meeting Abstract

Pike, L. R. G.; Wu, J.; Chen, M. H.; Loffredo, M.; Renshaw, A. A.; Pfail, J.; Kantoff, P. W.; D'Amico, A. V.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save